SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (273)12/18/2000 9:03:38 PM
From: Pseudo Biologist  Respond to of 1784
 
Tuck, well that was it for the "classic SI look." Switching to the newer style brings up all the portfolio links. I can see how my observation must have sounded non-sensical to anyone using the new interface look, which I guess is everybody but me these days -g-

Not surprised if most of the companies mentioned from the ACS calendar turn out to be private. TRPS is public and competes with PCOP in software and less so in combichem libraries and services. TRPS signed an interesting-sounding deal with bioinformatics outfit LEON a few months ago. If PCOP qualifies, I'd say TRPS should too at least for the watch list. Value is another story (which I have not reviewed in ages).

Taxonomy is the toughest thing; what you have looks good and pretty useful. I am not sure I have really good suggestions for improvement at this stage.

Thanks for the tips on portfolios,

PB



To: tuck who wrote (273)12/18/2000 11:10:13 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 1784
 
Cambrex rings bells. Suspect they are private or a division of someone else.

A lurker, TA, says "Nope. NYSE: CBM."

Further, they add that the trickle portion "is limited to the 100% ownership of BioWhitaker, LumiTech (this is a small UK outfit) and contract development work."

BioWhitaker...... in the olden days, lots of cell culture media, fetal bovine serum, etc. Don't know what they do now.